Mesa Laboratories Inc
NASDAQ:MLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (2.7), the stock would be worth $119.98 (21% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.2 | $99.42 |
0%
|
| 3-Year Average | 2.7 | $119.98 |
+21%
|
| 5-Year Average | 3.1 | $141 |
+42%
|
| Industry Average | 1.7 | $78.17 |
-21%
|
| Country Average | 2.4 | $109.13 |
+10%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$526.2m
|
/ |
Jan 2026
$247.5m
|
= |
|
|
$526.2m
|
/ |
Mar 2026
$255.6m
|
= |
|
|
$526.2m
|
/ |
Mar 2027
$269.4m
|
= |
|
|
$526.2m
|
/ |
Mar 2028
$276.8m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Mesa Laboratories Inc
NASDAQ:MLAB
|
549.3m USD | 2.2 | 147.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 16 | 56.3 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 3.6 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 4.8 | 37.2 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 2.9 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 4.1 | 23.6 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 7.6 | 43.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 1.7 | 18.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 10.2 | 41.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.9 | 23.8 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 5.8 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Mesa Laboratories Inc
Glance View
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 506 full-time employees. The firm operates through four segments, Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Instruments segment designs, manufactures, and markets quality control hardware and disposable products. The Continuous Monitoring segment develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure.
